Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

CG Oncology (CGON) EBITDA (2023 - 2025)

CG Oncology (CGON) has disclosed EBITDA for 3 consecutive years, with -$48.7 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBITDA fell 27.99% year-over-year to -$48.7 million, compared with a TTM value of -$190.8 million through Dec 2025, down 66.37%, and an annual FY2025 reading of -$190.8 million, down 66.37% over the prior year.
  • EBITDA was -$48.7 million for Q4 2025 at CG Oncology, up from -$51.1 million in the prior quarter.
  • Across five years, EBITDA topped out at -$9.7 million in Q1 2023 and bottomed at -$51.1 million in Q3 2025.
  • Average EBITDA over 3 years is -$30.1 million, with a median of -$27.1 million recorded in 2024.
  • The sharpest move saw EBITDA crashed 131.14% in 2024, then decreased 27.99% in 2025.
  • Year by year, EBITDA stood at -$19.4 million in 2023, then crashed by 96.58% to -$38.0 million in 2024, then fell by 27.99% to -$48.7 million in 2025.
  • Business Quant data shows EBITDA for CGON at -$48.7 million in Q4 2025, -$51.1 million in Q3 2025, and -$48.7 million in Q2 2025.